# Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

> **NCT03882580** · — · UNKNOWN · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 5000 (estimated)

## Conditions studied

- Cardiovascular Complication
- Cardiovascular Insufficiency
- Cardiac Complication
- Oncologic Complications
- Cardiac Insufficiency
- Metabolic Disorder
- Vascular Disorder
- Cardiac Disorder

## Interventions

- **DRUG:** Anti-Cancer Agents

## Key facts

- **NCT ID:** NCT03882580
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882580, "Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03882580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*